
TORONTO, April 6 /CNW/ - As previously announced, on March 26, 2009 the Special Committee of Independent Directors of Patheon Inc. ("Patheon") (TSX:PTI), delivered a request to the Ontario Securities Commission ("OSC") asking the OSC to review the legality of the unsolicited offer (the "Offer") by JLL Patheon Holdings LLC ("JLL") to acquire any and all of the issued and outstanding restricted voting shares (the "Restricted Voting Shares") of Patheon not owned by JLL or its affiliates. In its offering circular, JLL disclosed that, through a separate side deal, it is giving an option to receive special rights and protections to a group of Patheon shareholders (the "MOVA Group"), led by Joaquin Viso, who received Restricted Voting Shares when Patheon acquired MOVA Pharmaceutical Corporation in 2004.
The Special Committee has been advised by OSC staff that the OSC has received an application from JLL requesting a discretionary exemption from requirements relating to identical consideration and prohibitions against collateral agreements contained in the take-over bid provisions of Canadian securities laws. The Special Committee understands, from discussions with OSC staff, that OSC staff has requested that the OSC consider this application this week.
The Special Committee believes that it would be prejudicial to the public interest for the OSC to grant the requested relief. The Special Committee intends to actively oppose JLL's application and believes that such relief should not be granted without a full public hearing on both the application and the matters set out in Patheon's previously disclosed complaint to the OSC.
ABOUT PATHEON
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.
Patheon's integrated development and manufacturing network of 11 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.